



Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

2

Complete if Known

Application Number	10/736,188
Filing Date	December 15, 2003
First Named Inventor	Katherine Bowdish
Art Unit	1643
Examiner Name	Bradley Duffy

Attorney Docket Number ALEX-P03-060

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/BD/	AA1	US-7,238,352	07/03/2007	Gorcynski et al.	
	AA2	US-6,955,811	10-18-2005	Gorcynski et al.	
↓	AA3	US-20050169870-A1	08-04-2005	Truitt et al.	
	AA4	US-20050129690-A1	06-16-2005	Bowdish et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
/BD/	B3	WO-9428027	12-08-1994	Arch Dev Corp et al.	T ⁶

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
/BD/	C12	Caldas et al., "Humanization of the anti-CD18 antibody 6.7: an unexpected effect of a framework residue in binding to antigen," <i>Molecular Immunology</i> , 39(15):941-952 (2003).			T ²
	CJ2	Chien et al., Significant structural and functional change of an antigen-binding site by a distant amino acid substitution: Proposal of a structural mechanism," <i>PNAS</i> , 86(14):5532-5536 (1989).			
	CK2	Cochlovius et al., "Cure of Burkitt's Lymphoma in Severe Combined Immunodeficiency Mice by T Cells, Tetravalent CD3 X CD19 Tandem Diabloty, and CD29 Costimulation," <i>Cancer Research</i> , 60:4336-4341 (2000).			
	CL2	Ebert et al., Selective Immunosuppressive Action of a Factor Produced by Colon Cancer Cells," <i>Cancer Research</i> , 50:6158-6161 (1990).			
	CM2	Faisal et al., "Cell-surface Associated p43/Endothelial-monocyte-activating-polypeptide-II in Hepatocellular Carcinoma Cells Induces Apoptosis in T-lymphocytes," <i>Asian Journal of Surgery</i> , 30(1):13-22 (2007).			
	CN2	Ginaldi et al., "Levels of Expression of CD52 in Normal and Leukemic B and T Cells: Correlation with In Vivo Therapeutic Response to Campath-1H," <i>Leukemia Research</i> , 22(2):185-191 (1998).			
	CO2	Giusti et al., "Somatic diversification of S107 from an antiphosphocholine to an anti-DNA autoantibody is due to a single base change in its heavy chain variable region," <i>PNAS</i> , 84(9):2926-2930 (1987).			
↓	CP2	Hardy et al., "A lymphocyte-activating monoclonal antibody induces regression of human tumors in severe combined immunodeficient mode," <i>PNAS</i> , 94:5756-5760 (1997).			
	CQ2	Iwanuma et al., "Antitumor Immune Response of Human Peripheral Blood Lymphocytes Coengrafted with Tumor into Severe Combined Immunodeficient Mice," <i>Cancer Research</i> ,			

Examiner Signature	/Brad Duffy/	Date Considered	03/23/2008
--------------------	--------------	-----------------	------------



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/A/B/PTO

Complete if Known

 INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 2 Attorney Docket Number ALEX-P03-060

✓/BD	57.2937-2942(1997).	
	CR2 Liu et al., "Effect of combined T- and B-cell depletion of allogeneic HLA-mismatched bone marrow graft on the magnitude of kinetics of Epstein-Barr virus load in the peripheral blood of bone marrow transplant recipients," <i>Clinical Transplantation</i> , 18:518-524 (2004).	
	CS2 Mariuzza et al., "The Structural Basis of Antigen-Antibody Recognition," <i>Ann. Rev. Biophys. Chem.</i> , 16:139-159 (1987).	
	CT2 Mori et al., "Establishment of a new anti-cancer drugs-resistant cell line derived from B-chronic lymphocytic leukemia," <i>Proceedings, Fifty-Ninth Annual Meeting of the Japanese Cancer Association</i> , page 583, #3788 (September 1, 2000).	✓
	CU2 Riley, "Melanoma and the Problem Malignancy," <i>J. Exp. Med.</i> , 204:1-9 (2004).	
	CV2 Rudikoff et al., "Single amino acid substitution altering antigen-binding specificity," <i>PNAS</i> , 79:1979-1983 (1982).	
	CW2 Schulten et al., "Immunotherapy of Human Ovarian Carcinoma With Ovarex™ Mab-B43.13 in a Human-PBL-SCID/BG Mouse Model," <i>Hybridoma</i> , 18(1):47-55 (1999).	
	CX2 Snyder et al., "Enhanced Targeting and Killing of Tumor Cells Expressing the CXC Chemokine Receptor 4 by Transducible Anticancer Peptides," <i>Cancer Research</i> , 65(23):10646-10650 (2005).	
	CY2 Tanaka et al., "The Anti-Human Tumor Effect and Generation of Human Cytotoxic T Cells in SCID Mice Given Human Peripheral Blood Lymphocytes by the in Vivo transfer of the Interleukin-6 Gene Using Adenovirus Vector," <i>Cancer Research</i> , 57:1335-1343 (1997).	
	CZ2 Thomsen et al., "Reconstitution of a human immune system in immunodeficient mice: models of human alloreactivity in vivo," <i>Tissue Antigens</i> , 66:73-82 (2005).	
	CA3 Wright et al., "The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans," <i>Immunology</i> , 102:173-179 (2001).	
	CB3 Kneitz, C., et al., "Inhibition of Tcell/B cell interaction by B-CLL cells," <i>Leukemia</i> , 13:98-104 (1999).	
	CC3 Kretz-Rommel, A., et al., "CD200 Expression on Tumor Cells Suppresses Anti-Tumor Immunity: New Approaches to Cancer Immunotherapy," <i>J. Immunother.</i> , 29(6):666 (2006).	
	CD3 Kretz-Rommel, A., et al., "Immune Evasion by CD200: New Approaches to Targeted Therapies for Chronic Lymphocytic Leukemia," <i>J. Immunother.</i> , 28(6):650 (2005).	
	CE3 Kretz-Rommel, A., et al., "The Immuno-Regulatory Protein CD200 Is Overexpressed in a Subset of B-Cell Chronic Lymphocytic Leukemias and Plays a Role in Down-Regulating the TH1 Immune Response," <i>J. Immunother.</i> , 27(6):S46 (2004).	
↓	CF3 McWhirter, J.R., et al., "Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation," <i>PNAS</i> , 103(4):1041-1046 (2006).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Brad Duffy/	Date Considered	03/23/2008
--------------------	--------------	-----------------	------------